Fig. 1: Tumor dynamic responses to TDB monotherapies and mosunetuzumab + loncastuximab tesirine combination therapy in a prototypic patient. | npj Systems Biology and Applications

Fig. 1: Tumor dynamic responses to TDB monotherapies and mosunetuzumab + loncastuximab tesirine combination therapy in a prototypic patient.

From: QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy

Fig. 1

A Comparison of tumor dynamics between TDB monotherapies. The TDB monotherapies were dosed following their corresponding labels. B Comparison of tumor dynamics between mosunetuzumab monotherapy, loncastuximab tesirine monotherapy, and mosunetuzumab + loncastuximab tesirine combination therapy, following the dosing scheme proposed in the LOTIS-7 study as described in the Methods, with the first 2 loncastuximab tesirine doses at 150 µg/kg. For both simulations, the tumor was composed of CD19+CD20+ B cells and had an initial volume of 49.5 mL, with a doubling time of 23 days24. Lonca loncastuximab tesirine, TDB T-cell-dependent bispecific antibody.

Back to article page